Biocon Corporate Presentation
Biosimilars: Key updates in Q1 FY22
Biocon Biologics
KEY HIGHLIGHTS
Strong growth in BFI business with significant contribution
from COVID-19 portfolio, serving 50,000+ patients
Q1 FY22
Q 1 F Y 21
Revenue
*758Cr
*692Cr
Steady performance of non-COVID products
Continued improvement in market share for commercial
products in the US
Additional growth in US expected by launch of bBevacizumab
and bAspart, and bGlargine interchangeability
Near-term growth in EU to be driven by entry in new markets
and product launches (bBevacizumab)
10% YoY increase
Core EBITDA¹
*271Cr
*249Cr
36% of revenue
Profit Before Tax
*101Cr
*105Cr
1 Core EBITDA defined as EBITDA before R&D, forex and licensing income
13% of revenue
15% of revenue
13View entire presentation